Pancreatic cancer cell proliferation

Pancreatic cancer cell proliferation is a complex biological process characterized by the rapid and dysregulated division of malignant cells in the pancreas, primarily in pancreatic ductal adenocarcinoma (PDAC). It is not a single molecular target but a phenotypic outcome of multiple genetic alterations, most notably mutations in the KRAS oncogene (found in over 90% of cases) and the loss of tumor suppressors like TP53, CDKN2A, and SMAD4 (NIH, 2023). These mutations drive constitutive activation of signaling pathways such as MAPK/ERK and PI3K/AKT/mTOR, which promote cell cycle progression and survival (PubMed, PMC7075357). Therapeutic interventions aimed at controlling this proliferation include antimetabolites like Gemcitabine, which interfere with DNA synthesis, and newer targeted therapies like Sotorasib that inhibit specific KRAS mutations (Nature Reviews Drug Discovery, 2022). Monitoring proliferation often involves biomarkers like Ki-67 for cellular growth rates and CA 19-9 for clinical progression (PubMed, 31510066).

Other names

Pancreatic tumor growthPDAC cell proliferationPancreatic cancer growthPancreatic ductal adenocarcinoma proliferation

Inhibition of DNA replication, disruption of microtubule assembly, or blockade of oncogenic signaling cascades (e.g., KRAS/MAPK) to induce cell cycle arrest or apoptosis.